Enoxaparin Treatment Guidelines for Venous Thromboembolism

Standard Treatment Regimens

The American College of Cardiology recommends a standard treatment dose of enoxaparin of 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily for therapeutic anticoagulation in venous thromboembolism (VTE) 1, 2, 3
The European Heart Journal suggests that 1 mg/kg subcutaneously every 12 hours is the most established therapeutic regimen for DVT/PE treatment, proven equivalent to unfractionated heparin for both efficacy and safety in large prospective trials 1, 2, 4

For patients with severe renal impairment (CrCl <30 mL/min), the American College of Cardiology recommends reducing the dose to 1 mg/kg subcutaneously once daily, as enoxaparin clearance is reduced by 44% in severe renal failure, increasing bleeding risk nearly 4-fold without dose adjustment 1, 6
For obese patients (BMI ≥40 kg/m²), the Journal of the National Comprehensive Cancer Network recommends using 0.8 mg/kg subcutaneously every 12 hours, as a randomized trial showed 89.3% of patients on reduced-dose reached goal anti-Xa levels versus 76.9% on standard dosing 4, 5

The European Heart Journal recommends a minimum of 5-10 days for initial treatment of acute DVT/PE, with provoked VTE treated for exactly 3 months if due to reversible risk factor, and unprovoked VTE treated for a minimum of 3-6 months initially, then considering indefinite therapy 2, 5
The Journal of the National Comprehensive Cancer Network recommends a minimum of 6 months of treatment for cancer-associated VTE, indefinitely while cancer is active 4, 5

The European Heart Journal recommends routine monitoring of platelet count every 2-3 days from day 4 to day 14 to screen for heparin-induced thrombocytopenia, as well as hemoglobin and hematocrit every 2-3 days for the first 14 days, then every 2 weeks 2, 5, 6
The Journal of the National Comprehensive Cancer Network recommends anti-Xa level monitoring when indicated, such as in severe renal impairment, pregnancy with therapeutic doses, morbid obesity, and patients <50 kg or >150 kg, with a target range of 0.6-1.0 IU/mL for twice-daily dosing and 1.0-1.5 IU/mL for once-daily dosing 4, 3, 5

The European Heart Journal lists absolute contraindications for enoxaparin, including active major bleeding and severe thrombocytopenia (platelet count <50,000/μL) 2
The Journal of the National Comprehensive Cancer Network recommends avoiding neuraxial anesthesia within 10-12 hours before spinal/epidural procedures to prevent spinal hematoma, and waiting 24 hours after the block before restarting therapeutic doses of enoxaparin 3, 5